Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report released on Monday morning,Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $1.93 on Monday. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market capitalization of $395.54 million, a PE ratio of 3.06 and a beta of 0.95. The business’s fifty day moving average price is $2.10 and its 200 day moving average price is $2.14.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in Taysha Gene Therapies by 1.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock worth $6,033,000 after purchasing an additional 37,844 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth about $201,000. Barclays PLC grew its holdings in shares of Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after buying an additional 193,046 shares during the last quarter. Geode Capital Management LLC increased its position in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after acquiring an additional 682,273 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $931,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.